Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Anticipated CAGR of the Oncology Companion Diagnostics Market, and What Factors Will Drive It?
Over the past few years, the size of the oncology companion diagnostics market has seen accelerated expansion. The market value is set to rise from $3.35 billion in 2024 and achieve $3.79 billion by 2025, displaying a compound annual growth rate (CAGR) of 13.2%. The historic growth is due to factors such as the rise in adverse drug reaction cases, expanding demand for thorough genomic testing, climbing global cancer rates, heightened requirements for targeted therapy, and an increase in the number of clinical trials.
In the coming years, the oncology companion diagnostics market size is poised for a rapid expansion, with projections of reaching$5.96 billion by 2029 and a compound annual growth rate (CAGR) of 12.0%. This expected growth over the forecast period is associated with the rising value of personalized medicine, an upsurge in diagnostic tests, a heightened focus on tailored cancer therapy, an escalation in healthcare spending, and an increase in cancer awareness and occurrence. The forecast period also considers the influence of major trends such as enhancements in diagnostic technologies, developments in next-generation sequencing (NGS), the incorporation of artificial intelligence (AI), advancements in liquid biopsy technologies, the emergence of point-of-care companion diagnostic devices, and innovative testing technologies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15623&type=smp
What Are the Core Growth Drivers Propelling the Oncology Companion Diagnostics Market Forward?
The oncology companion diagnostics market is forecasted to expand, driven by the anticipated increase in cancer prevalence. Cancer consists of a diverse set of illnesses caused by uncontrolled and abnormal cell growth and expansion in the body. The surge in cancer occurrences is attributed to lifestyle alterations, environmental influences, the obesity crisis, tobacco usage, and genetic determinants. Oncology companion diagnostics play a crucial role in precision oncology strategies, transforming cancer treatment by fostering personalized therapy selection, enhancing therapy effectiveness, reducing unwanted side effects, aiding in clinical trial participation, and improving therapy monitoring. For example, in May 2024, the National Cancer Institute, a US governmental agency, logged approximately 20 million fresh cases and 9.7 million cancer-associated mortalities annually in 2022, and forecasts suggest that by 2040, the numbers will reach 15.3 million deaths and 29.9 million fresh cases per year. Consequently, the upsurge in cancer incidents fuels the growth of the oncology companion diagnostics market.
What Segment Types Define the Oncology Companion Diagnostics Market Structure?
The oncology companion diagnosticsmarket covered in this report is segmented –
1) By Product: Instrument; Consumables; Software
2) By Disease Type: Melanoma; Breast Cancer; Colorectal Cancer; Leukemia; Prostate Cancer; Other Disease Types
3) By Technology: Immunohistochemistry (IHC); In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH); Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Other Technologies
4) By End User: Hospital; Pathology Or Diagnostic Laboratory; Academic Medical Center; Other End-Users
Subsegments:
1) By Instrument: Polymerase Chain Reaction (Pcr) Instruments; Next-Generation Sequencing (Ngs) Systems; Immunohistochemistry (Ihc) Instruments; Fluorescence In Situ Hybridization (Fish) Instruments; Microarray Platforms
2) By Consumables: Reagents And Kits (Dna Or Rna Extraction Kits, Pcr Reagents); Biopsy Needles; Testing Slides And Chips; Control And Calibration Samples
3) By Software: Data Analysis Software; Bioinformatics Software ( For Gene Expression Analysis); Companion Diagnostic Decision Support Software; Clinical Workflow Management Software
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15623&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Oncology Companion Diagnostics Market?
North America was the largest region in the oncology companion diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing theOncology Companion Diagnostics Industry Evolution?
In the field of oncology companion diagnostics, leading corporations are aiming to maintain their market foothold by developing unique products like in vitro diagnostic examinations. These tests, typically known as IVD tests, are clinical procedures performed on human samples, such as blood or tissue, in regulated surroundings such as labs, outside of the human body. For example, Illumina Inc., a biotechnology company from the United States, introduced a new pan-cancer companion diagnostic (CDx) aspect to their in-vitro diagnostic product, TruSight Oncology (TSO) Comprehensive (EU) in May 2022. This diagnostic tool allows for extensive tumor profiling by evaluating multiple tumor genes and biomarkers, giving medical practitioners the ability to make informed decisions regarding cancer treatment targeted towards patients with solid malignant tumors. The test measures the tumor mutational burden (TMB) score and microsatellite instability (MSI) status, enhancing the accuracy and potency of treatment plans.
View the full report here:
What Is the Definition of the Oncology Companion Diagnostics Market?
Oncology companion diagnostics are medical tests that identify specific biomarkers, indicating which patients are most likely to benefit from a particular cancer treatment. These diagnostics are essential for developing and applying targeted therapies, as they help ensure that treatments are tailored to the individual characteristics of a patient’s tumor. Companion diagnostics provide insights into the molecular and genetic profile of the cancer, enabling more personalized and effective treatment plans, improving outcomes, and minimizing unnecessary side effects.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15623
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model